Virology and Immunology of HIV/AIDS

Understanding HIV: Virology and Immunology

Human Immunodeficiency Virus (HIV) remains a major global health challenge. This course breaks down the virus’s structure, life cycle, and the host immune responses that shape disease progression. By mastering these concepts, medical students and clinicians can improve diagnosis, treatment, and prevention strategies.

1. Viral Structure and the First Contact with Host Cells

The HIV particle is an enveloped retrovirus composed of:

• gp120: a surface glycoprotein that binds the CD4 receptor on target cells and engages coreceptors (CCR5 or CXCR4).
• gp41: a transmembrane protein that mediates the fusion of viral and cellular membranes after gp120 attachment.
• Internal enzymes such as reverse transcriptase, integrase, and protease.

Key point: The initial attachment is mediated by gp120 binding to CD4. Without this interaction, the virus cannot enter the cell.

2. Early Steps of the HIV Life Cycle

Once gp120 binds CD4 and a coreceptor, the viral envelope fuses with the host membrane, releasing the viral capsid into the cytoplasm. The next critical step is the conversion of the single‑stranded RNA genome into double‑stranded DNA.

• Reverse Transcriptase (RT): synthesizes complementary DNA (cDNA) from the viral RNA template. This enzyme lacks proofreading ability, leading to a high mutation rate.

Quiz insight: The correct answer to “After HIV entry, which enzyme converts the viral RNA genome into DNA?” is Reverse transcriptase.

3. Integration and the Latent Reservoir

Following reverse transcription, the newly formed proviral DNA is transported into the nucleus where integrase inserts it into the host genome. Integration creates a stable, latent reservoir that can persist for years.

• Latent proviruses are transcriptionally silent, evading immune detection.
• They reside primarily in long‑lived CD4+ T cells and macrophages.

Why latency matters: The provirus’s integration allows HIV to hide from both the immune system and antiretroviral drugs, necessitating lifelong therapy.

4. Primary Cellular Targets of HIV

HIV preferentially infects cells expressing CD4 and the appropriate coreceptor:

• CD4+ T lymphocytes: the main target; depletion leads to immunodeficiency.
• Macrophages: express CCR5 and serve as viral reservoirs.
• Dendritic cells: capture virus and transmit it to T cells (trans‑infection).

Neutrophils lack CD4 receptors and are therefore not primary targets for HIV infection.

5. The Role of the Immune System in Early HIV Infection

During the acute phase, the innate and adaptive arms of immunity collaborate:

• Natural Killer (NK) cells: provide early antiviral activity but do not specifically block gp120.
• CD8+ Cytotoxic T Lymphocytes (CTLs): recognize viral peptides presented on MHC I and kill infected cells, reducing viral load.
• B cells: eventually produce neutralizing antibodies, though not immediately.

The primary immune response that curtails early replication is the activity of CD8+ CTLs.

6. Viral Evolution and Immune Escape

HIV’s rapid replication (up to 10^10 virions per day) and error‑prone reverse transcriptase generate a diverse quasispecies pool. This diversity enables the virus to:

• Mutate epitopes recognized by CD8+ T cells, escaping cytotoxic pressure.
• Develop resistance to antiretroviral drugs.

Thus, the main reason HIV mutants evade CD8+ T‑cell pressure is the rapid generation of diverse epitope mutations.

7. Transmission Pathways

HIV is transmitted through direct contact with infected bodily fluids. Common routes include:

• Sexual intercourse (vaginal, anal, oral).
• Sharing contaminated needles.
• Mother‑to‑child transmission (placental, birth, breastfeeding).

Airborne transmission via droplets does not occur, distinguishing HIV from respiratory viruses.

8. Clinical Implications and Prevention Strategies

Understanding the virology and immunology of HIV informs several key clinical practices:

• Testing and Diagnosis: Detect viral RNA (PCR) or antibodies (ELISA) early to initiate treatment.
• Antiretroviral Therapy (ART): Combines drugs targeting reverse transcriptase, integrase, and protease to suppress replication and limit reservoir formation.
• Pre‑Exposure Prophylaxis (PrEP): Daily oral tenofovir/emtricitabine reduces acquisition risk in high‑risk populations.
• Vaccination Research: Efforts focus on eliciting broadly neutralizing antibodies against gp120 and robust CTL responses.

9. Summary of Core Concepts

To master HIV virology and immunology, remember these pivotal points:

• gp120‑CD4 interaction initiates infection.
• Reverse transcriptase converts RNA to DNA.
• Integration creates a latent provirus that evades immunity.
• Primary targets: CD4+ T cells, macrophages, dendritic cells; neutrophils are not infected.
• Early viral control relies on CD8+ cytotoxic T cells.
• High replication rate drives rapid mutation and immune escape.
• Transmission requires direct fluid contact; airborne spread does not occur.

10. Frequently Asked Questions (FAQ)

Q Minis: Why can HIV remain hidden for years?

Answer: After integration, proviral DNA can stay transcriptionally silent, forming a latent reservoir that is invisible to the immune system and unaffected by most drugs.

Q: Can a vaccine prevent HIV infection?

Answer: An effective vaccine would need to induce both broadly neutralizing antibodies against gp120 and strong CD8+ T‑cell responses, a challenge still under active investigation.